Sidewinder Therapeutics

About Sidewinder Therapeutics

Sidewinder Therapeutics is a biotechnology company focused on pioneering the next generation of bispecific antibody-drug conjugates (ADCs). Their mission is to deliver innovative therapies that expand the therapeutic window for patients with difficult-to-treat cancers, leveraging a team of serial entrepreneurs, expert scientists, and drug developers.

Products & Services

Bispecific Antibody-Drug Conjugates (ADCs):Engineered to target receptor co-complexes highly expressed on certain solid tumors, enhancing tumor cell specificity and internalization for improved cancer treatment.

Specialties

Bispecific Antibody-Drug Conjugates (ADCs) Precision Oncology Solid Tumor Targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 137000000 MR: - FA: 137 million FAN: 137000000	D: 2026-04-08 FD: 2026-04-08	9 investors

Series B Latest

2026-04-08

$137.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Patrick A. Zweidler-McKay

Chief Medical Officer

V

Valerie Odegard

Scientific Advisor

L

Laurie Tatalick

Non-Clinical & Toxicology

M

Morris Rosenberg

CMC Strategy and Management

M

Michal Silverberg

Director

J

Josh Richardson

M.D.

View 14 more team members with Pro

Unlock Full Team Directory

Recent News